Laekna, Inc. (HKG:2105)

Market Cap	7.27B
Revenue (ttm)	557.63K
Net Income (ttm)	-270.61M
Shares Out	373.62M
EPS (ttm)	-0.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,636,500
Average Volume	5,719,628
Open	19.08
Previous Close	19.08
Day's Range	18.30 - 19.50
52-Week Range	3.90 - 20.35
Beta	-0.71
RSI	65.17
Earnings Date	May 16, 2025

About Laekna

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People’s Republic of China, the United States of America, and South Korea. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 86
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2105

Financial Performance

In 2024, Laekna's revenue was 524,000, an increase of 11.49% compared to the previous year's 470,000. Losses were -254.30 million, -31.05% less than in 2023.

Financial numbers in CNY